Arcutis Biotherapeutics's Total Assets for the quarter that ended in Mar. 2024 was $478.5 Mil.
During the past 12 months, Arcutis Biotherapeutics's average Total Assets Growth Rate was 58.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 71.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 185.00% per year.
During the past 7 years, Arcutis Biotherapeutics's highest 3-Year average Total Assets Growth Rate was 411.10%. The lowest was 71.30%. And the median was 157.95%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Arcutis Biotherapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcutis Biotherapeutics (NAS:ARQT) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Arcutis Biotherapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Arcutis Biotherapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Arcutis Biotherapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Arcutis Biotherapeutics (Arcutis Biotherapeutics) Business Description
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARQT has been successfully added to your 